

# Fernando Ramos Lopez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7180134/publications.pdf>

Version: 2024-02-01

10  
papers

1,350  
citations

1040056

9  
h-index

1372567

10  
g-index

10  
all docs

10  
docs citations

10  
times ranked

2578  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. <i>Lancet Microbe</i> , The, 2022, 3, e11-e20.	7.3	25
2	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	30.7	265
3	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	30.7	473
4	Safety and Immunogenicity of Adenovirus and Poxvirus Vected Vaccines against a Mycobacterium Avium Complex Subspecies. <i>Vaccines</i> , 2021, 9, 262.	4.4	3
5	Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. <i>Lancet</i> , The, 2021, 397, 1809-1818.	13.7	253
6	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. <i>Med</i> , 2021, 2, 701-719.e19.	4.4	73
7	A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. <i>Nature Communications</i> , 2021, 12, 4636.	12.8	31
8	Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assembly. <i>JCI Insight</i> , 2021, 6, .	5.0	22
9	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 816-826.	9.1	182
10	Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. <i>Vaccines</i> , 2019, 7, 33.	4.4	23